BHVN rises on SK Biopharmaceuticals epilepsy drug license
BHVN is trading higher following SK Biopharmaceuticals’ license for an epilepsy drug, with retail now awaiting an obesity trial readout.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.